Biogen vs Royalty Pharma

Biogen (BIIB), health care, and Royalty Pharma (RPRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Royalty Pharma is worth $39.5B on the stock market and Biogen $37.1B: Royalty Pharma is valued at 7% more. Biogen trades at 109 times earnings and Royalty Pharma at 44.9. Over the past year Biogen's share price has moved +49.1% and Royalty Pharma's +73.7%.

Key facts

Biogen market value
$37.1B
Royalty Pharma market value
$39.5B
Biogen P/E
109
Royalty Pharma P/E
44.9
Biogen revenue
$9.9BFY to 2025-12-31
Royalty Pharma revenue
$2.4BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Biogen vs Royalty Pharma: every measure side by side
Measure Biogen Royalty Pharma
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$37.1Blower$39.5Bhigher
Revenue$9.9Bhigher$2.4Blower
Earnings$1.3Bhigher$770.9Mlower
Employees7,500higher100lower
Total assets$29.4Bhigher$19.6Blower
Valuation
P/E109higher44.9lower
P/S3.7lower16.6higher
P/B2.0lower4.5higher
Dividend yield0.00%lower1.35%higher
Profitability
Operating margin—65.6%
Balance sheet
Net assets$18.3Bhigher$9.7Blower
Total liabilities$11.2Bhigher$9.9Blower
Total debt$6.3Blower$9Bhigher
Cash on hand$3Bhigher$618.7Mlower
Price change
Today-0.34%lower+0.23%higher
1 year+49.1%lower+73.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Royalty Pharma only (4)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Biogen / Royalty Pharma). Who owns BIIB · Who owns RPRX

Further comparisons

Learn

Questions and answers

Which is bigger, Biogen or Royalty Pharma?

By market value, Royalty Pharma is the larger: $39.5B against $37.1B for Biogen. By revenue in its latest fiscal year, Biogen is the larger: $9.9B against $2.4B for Royalty Pharma.

Which has the higher P/E ratio?

Biogen: 109, against 44.9 for Royalty Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Royalty Pharma: 1.35%, against 0.00% for Biogen. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Royalty Pharma: $9B, against $6.3B for Biogen. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Biogen and Royalty Pharma?

In their latest 13F filings, Samantha McLemore holds both.

Cite this page

Funkfolio, “Biogen vs Royalty Pharma”, data as of 18 November 2026. https://funkfolio.com/compare/biib-vs-rprx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.